Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ELANE | P08246 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | ACR | P10323 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26824432 | 1.00 | LMNA (0.52) | LMNAELANEALDH1A1PRSS1ACR | |
| SCHEMBL28774783 | 0.85 | ELANE (0.46) | LMNAELANEALDH1A1GAAMAPT | |
| SCHEMBL28774781 | 0.85 | ELANE (0.46) | LMNAELANEALDH1A1GAAMAPT | |
| SCHEMBL5058438 | 0.85 | LMNA (0.55) | LMNAELANEALDH1A1PRSS1ACR | |
| SCHEMBL27498354 | 0.85 | LMNA (0.55) | LMNAELANEALDH1A1PRSS1ACR | |
| SCHEMBL28774734 | 0.84 | ELANE (0.44) | LMNAELANEALDH1A1MAPTKMT2A | |
| SCHEMBL28774735 | 0.84 | ELANE (0.44) | LMNAELANEALDH1A1MAPTKMT2A | |
| SCHEMBL28774785 | 0.84 | ALDH1A1 (0.46) | ELANEALDH1A1GAAKMT2ACYP1A2 | |
| SCHEMBL28774787 | 0.84 | ALDH1A1 (0.46) | ELANEALDH1A1GAAKMT2ACYP1A2 | |
| SCHEMBL28044955 | 0.84 | ELANE (0.44) | LMNAELANEMAPTKMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325914-B1 | Inhibitors of cellular metabolic processes | SERVIER PHARMACEUTICALS LLC (US) | 2022-05-10 | — | — | US | disclosed |
| WO-2021158792-A1 | METHODS OF TREATING AUTOIMMUNE OR INFLAMMATORY DISEASES OR DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-10800782-B2 | Inhibitors of cellular metabolic processes | Agios Pharmaceutical, Inc. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190233424-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | SERVIER PHARMACEUTICALS LLC | 2019-08-01 | — | — | US | disclosed |
| US-10329298-B2 | Inhibitors of cellular metabolic processes | AGIOS PHARMACEUTICALS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180079753-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | SERVIER PHARMACEUTICALS LLC | 2018-03-22 | — | — | US | disclosed |
| US-20180079753-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | SERVIER PHARMACEUTICALS LLC | 2018-03-22 | — | — | US | disclosed |
| WO-2018039972-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | AGIOS PHARMACEUTICALS, INC. (US) | 2018-03-08 | — | — | WO | disclosed |
| US-9822115-B2 | Nitrogen containing compounds and their use as antibacterial agents | WOCKHARDT LIMITED (IN) | 2017-11-21 | — | — | US | disclosed |
| US-20160355516-A1 | NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | WOCKHARDT LIMITED (IN) | 2016-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329298-B2 | Inhibitors of cellular metabolic processes | MNAT1, MAT2A, PCK2 | LMNA 2806/4885ELANE 4445/4885ALDH1A1 352/4885 |
| US-20190233424-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | MNAT1, MAT2A, PCK2 | LMNA 2806/4885ELANE 4445/4885ALDH1A1 352/4885 |
| US-10800782-B2 | Inhibitors of cellular metabolic processes | MNAT1, MAT2A, PCK2 | LMNA 2806/4885ELANE 4445/4885ALDH1A1 352/4885 |
| US-20180079753-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | MNAT1, MAT2A, PCK2 | LMNA 2806/4885ELANE 4445/4885ALDH1A1 352/4885 |
| US-20160355516-A1 | NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | NOS2, NOS1, NCF1 | LMNA 2613/4885ELANE 6/4885ALDH1A1 2447/4885 |
| US-11325914-B1 | Inhibitors of cellular metabolic processes | MNAT1, MAT2A, PCK2 | LMNA 2806/4885ELANE 4445/4885ALDH1A1 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.